

# Fostering Innovation in Vector Borne Parasitic Diseases through Young Researcher Innovators within CA21111 OneHealthdrugs

**Elisa Uliassi,<sup>a</sup> Clara Lima,<sup>b,c</sup> Chiara Borsari,<sup>d</sup> Gülşah Bayraktar,<sup>e</sup> Kayhan Ilbeigi,<sup>f</sup> Maria Laura Bolognesi,<sup>a</sup> Anabela Cordeiro-da-Silva,<sup>b,c</sup> Maria Paola Costi<sup>g</sup>**

<sup>a</sup> Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy; <sup>b</sup> Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal; <sup>c</sup> Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal; <sup>d</sup> Department of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy; <sup>e</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, Izmir 35100, Turkey; <sup>f</sup> Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, 2610 Wilrijk, Belgium; <sup>g</sup> Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy

## COST Action CA21111 OneHealthdrugs

**COST Action CA21111 - OneHealthdrugs** “One Health drugs against parasitic vector borne diseases in Europe and beyond” (<https://www.cost.eu/actions/CA21111/>) is a **consortium of researchers dedicated to improving drug development for Vector Borne Parasitic Diseases (VBPD) of humans and animals**, through coordination of the **discovery of drugs that help control human and veterinary VBPD, adhering to the principles of the optimal profile for all organisms, while reducing the environmental impact of their associated research and the resulting new treatments.**


## Young Researcher Innovators (YRI) Horizontal Group (HG) 4

**HG4 is composed by 97 YRI (< 40 years).** HG4 aims to **stimulate YRI research, training and networking activities** across all areas of VBPD, by **creating new knowledge and technologies** according to the *One Health* goals.

**HG4 is also committed to raise awareness and to make VPBD research more environment-conscious.**



**Dr Elisa Uliassi**  
University of Bologna (IT)  
HG4 leader  
[elisa.uliassi3@unibo.it](mailto:elisa.uliassi3@unibo.it)



**Dr Clara Lima**  
University of Porto (PT)  
HG4 vice-leader  
[clara.lima@i3s.up.pt](mailto:clara.lima@i3s.up.pt)

**WHO** **53 countries**, of which **20 ITC**  
**273 members**  
Chair **Prof MP Costi (IT)**  
Vice-Chair **Prof A Cordeiro-da-Silva (PT)**

**WHY** There is an urgent need to **stop VBPD in both human and veterinary settings** according to the **One Health principles.**

**WHAT** **WG1-6 and HG1-7 activities cover VPBD drug discovery research, ecotoxicology aspects, dissemination and communication**

**HOW** **CA21111 and HG4 include a wide range of activities and opportunities. Some of them are exclusively dedicated to YRI!!**



## Short-term Scientific Missions (STSMs):

**STSMs are interlaboratory exchange visits on OHD topics and particularly intended for YRIs.** These aim at strengthening the existing COST Actions by allowing scientists to go to an institution or laboratory in another COST country to foster collaboration, to learn a new technique or to use/apply instruments and/or methods not available in their own institution/laboratory. The STSM should last up to 6 months and shall be made within the time frame of the operation identified in the proposal and within the period of the respective Action. The financial support offer is a contribution to the overall expenses during the STSM (cover travel and subsistence expenses and is paid as a grant). The next grant application period starts in **October 2024** and all STSMs must be completed by **August 31, 2025.**

## OHD Marathon:

CA21111 OneHealthDrugs organizes every the **OHD Marathon in November to celebrate the One Health Day** – an international event established by the One Health Commission (<https://www.onehealthcommission.org>) - with **3-days of non-stop OHD presentations** and **a session dedicated to YRI along with two YRI awards for the best presentations!**



## OHD surveys:



CA21111 OneHealthDrugs is implementing several survey investigating different OHD topics: *WG1 Compound Databases Survey*, *WG6-HG4 survey on One Health and sustainability principles integration into PVBD drug discovery and development* <https://www.onehealthdrugs.com/working-area/surveys/compound-databases-survey/>

## Women in STEM initiative:

CA21111 OneHealthDrugs celebrates the **International Day of Women and Girls in Science** with dedicated activities: **a collection of interviews to OHD women scientists** is available at



<https://www.onehealthdrugs.com/women-in-stem/women-in-stem-onehealthdrugs-cost-action/> and a **YOUTUBE video** available at <https://www.youtube.com/watch?v=ZM8QZTP-fDE>



## Conference and ITC Conference Grants:

These grants are aimed at enhancing research collaboration where ideas and YRIs and PhD students from Inclusive Target Countries (ITC) can grow without borders by helping individuals to attend beneficial international conferences that are **not organized by COST Actions.** YRI who is affiliated with an institution located in an ITC country participating in the OHD can submit an application request for an ITC Conference Grant and must deliver an oral presentation at the conference. The application must be submitted at least 45 days before the conference start date. The next grant application period starts in **October 2024.**

## Training Schools:

CA21111 OneHealthDrugs organizes two Training Schools per year aimed at training YRI on OHD topics. **The next Training School will be on Cell culture as in vitro models for VBPD drugs, 25-27 Sept 2024, Poland.**



## Stay Tuned! Next events, WG-HG meetings and workshops:

CA21111 OneHealthDrugs organizes several on-line and in-presence WG-HG meetings and workshops related to different topics. Check all scheduled OHD events in 2024 at <https://www.onehealthdrugs.com/events/calendar-of-onehealthdrugs-events-year-2-2024>

**Next in-person event: Advancements in Structural and Functional Drug Discovery of VBPD. 3-5 July 2024 Oxford**

## Special Issue One Health and VBPD in ACS Infectious Diseases:



This Special Issue will highlight the development of drugs against human and animal vector-borne parasitic disease (VBPD) using innovative technologies with minimal environmental risks. See the Editorial by Profs Costi & Cordeiro-da-Silva

<https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00304>



**OHD newsletter:** containing news and updates concerning all OHD activities, past and future events and dissemination outputs

## OHD social media:

**XIII Meeting Paul Ehrlich Euro-PhD Network & COST ACTION**  
One Health approach to tackle neglected infectious diseases challenges

## FOLLOW US

